MicroRNA Regulation of Cancer Stem Cells

Can Liu1,2 and Dean G. Tang1,2,3

Abstract
Cancer stem cells (CSC), or cancer cells with stem cell properties, have been reported in many human tumors and are thought to be responsible for tumor initiation, therapy resistance, progression, relapse, and metastasis. Despite their potential clinical importance, how CSCs are regulated at the molecular level is not well understood. MicroRNAs (miRNA), small noncoding RNAs that play critical roles in normal stem cell functions, have been discovered in acute myeloid leukemia and, since 2003, have also been reported in most solid tumors (1). Emerging evidence indicates that CSCs may be involved in tumor maintenance, therapy resistance, tumor progression, and distant metastasis. Despite their potential clinical significance, how intrinsic CSC properties are regulated at the molecular level is poorly understood. Recent discoveries of microRNAs (miRNA) have provided a new avenue in understanding the regulatory mechanisms in CSCs.

miRNAs are 21- to 25-nucleotide (nt)–long, noncoding RNAs that induce the target mRNA degradation or repress mRNA translation by imperfect binding to their 3’-untranslated region (2). The miRNA gene is first transcribed by RNA polymerase II into primary transcript (pri-miRNA) in the nucleus, where the hairpin stem-loop structure is processed into precursor miRNA (pre-miRNA) by a microprocessing complex, including Drosha and DGCR8. The ~70-nt-long pre-miRNA is then exported into cytoplasm, where it undergoes a second processing by Dicer, in which one strand of the hairpin is incorporated into the ribonucleoprotein complex called miRNA-induced silencing complex (2). A single miRNA may target dozens of mRNAs, and one mRNA can be regulated by multiple miRNAs. Although small, miRNAs play a powerful role in biological processes including development, proliferation, and apoptosis. Early studies have linked miRNAs to controlling the self-renewal and differentiation of embryonic stem cells (ESC), and later, aberrant expression and/or functions of miRNAs are implicated in tumorigenesis (3). More recent studies suggest that miRNAs may also regulate CSC properties.

miRNA Regulation of Development and Embryonic Stem Cells

The first 2 miRNAs, lin-4 and let-7, were both discovered during Caenorhabditis elegans development. Since then, miRNAs have emerged as important regulators of embryonic development and stem cell functions in mammals. The overall roles of miRNAs in both mouse and human ESCs have been evaluated by analyzing the phenotypes of Dicer and DGCR8 mutants. Deletion of Dicer in mouse causes embryonic lethality (4), and Dicer-deficient mouse ESCs exhibit defects in differentiation and G1 cell-cycle arrest (5). Similarly, DGCR8-deficient mouse ESCs show problems in cell-cycle progression and differentiation, evidenced by failing to silence self-renewal genes, such as OCT4, REX1, NANOG, and SOX2, as well as delayed expression of differentiation markers (6). Other studies have also revealed specific expression and functions of individual miRNAs in ESCs (7).

A regulatory circuitry between miRNAs and "pluripotency" genes required for maintaining ESC stemness has been identified. On one hand, the master regulators of stem cell pluripotency, including OCT-4, NANOG, SOX2, and TCF3, all
directly regulate ESC-specific miRNAs by binding to their promoter regions (8). On the other hand, some of these pluripotency genes are also regulated by miRNAs at the posttranscriptional level. Thus, miR-134, miR-296, and miR-470 suppress the expression of NANOG, OCT4, and SOX2 binding to their coding regions (9). Lin-28, a marker of undifferentiated ESCs that is used to generate induced pluripotent stem cells, also forms a negative feedback loop with the let-7 family miRNAs to precisely control each other's levels. Lin-28 regulates the expression of let-7 by binding to the precursors and blocking their maturation, whereas in differentiated cells where let-7 levels are increased, let-7 miRNAs, in turn, target the Lin-28 mRNA (10).

**miRNA Regulation of Cancer and Cancer Stem Cells**

Interestingly, the miRNA expression patterns in tumor cells often bear resemblance to those in ESCs. Let-7, for instance, is excluded in ESCs and often lost in cancers, including breast, lung, and ovarian cancers. Such cancer-specific miRNA expression signature(s) may become very informative for diagnostic and prognostic purposes. Functional studies of the dysregulated miRNAs indicate that they regulate molecular pathways in cancer via targeting different oncogenes and/or tumor suppressors. More recent evidence suggests that miRNAs may also be involved in tumor development by critically regulating CSCs. Here, we discuss the major findings of some recent studies highlighting the roles of certain "CSC-specific" miRNAs in several representative cancer types. From these discussions, we present an emerging theme that several miRNAs may distinctively and concertedly (coordinate) regulate the key biological properties of CSCs.

**Differential expression of miRNAs in cancer stem cells**

Yu and colleagues were the first to examine the miRNA expression in breast CSCs (BCSC; ref. 11). The authors enriched BCSCs by consecutively passaging breast cancer cell SKBR3 in mice treated with chemotherapy. The tumors were shown to contain a high percentage of CD44^+CD24^-/lo cells and high ability to form mammospheres in vitro and tumors in vivo. Importantly, the BCSC-enriched cells expressed much lower levels of let-7 as well as a number of other miRNAs, including miR-16, miR-107, miR-128, and miR-20b, than the parental cells and the in vitro differentiated progeny (11). Later, Shimono and colleagues identified 37 miRNAs to be differentially expressed in CD44^+CD24^-/lo BCSCs, in which 3 clusters, miR-200c-141, miR-200b-200a-429, and miR-183-96-182, were significantly downregulated (12). Notably, these miRNAs were markedly reduced in normal mammary stem and/or progenitor cells as well. In glioblastoma multiforme (GBM), some miRNAs, including miR-451, miR-486, miR-425, miR-16, miR-107, and miR-185, were decreased in the CD133^+ population (13). In hepatocellular carcinoma (HCC), EpCAM^+AFP^+ CSCs expressed a unique miRNA signature with upregulation of miR-181 family members and several miR-17-92 cluster members (14). Through unbiased miRNA expression profiling, our group recently showed that prostate cancer stem and/or progenitor cell populations enriched with surface markers CD44, CD133, or α2β1 prominently and commonly underexpress miR-34a and let-7b (15).

**Breast cancer stem cells**

BCSCs were the first CSCs to be reported and are among the best characterized of all CSCs in solid tumors. BCSCs are most commonly enriched using the CD44^+CD24^-/lo marker profile (12) or Aldefluor assays (16). Because of the early discovery and better understanding of BCSCs, miRNA studies in these cells are also more advanced than in other CSCs. On the basis of profiling results that let-7 was significantly reduced in BCSCs (11), Yu and colleagues further unraveled that let-7 regulated the stem cell properties, that is, self-renewal and differentiation. Lentiviral-mediated overexpression of let-7a inhibited cell proliferation, mammosphere formation, tumor formation, and metastasis in nonobese diabetic (NOD)/severe combined immunodeficient mice enhanced in vitro propagation of non-CSCs. H-RAS and HMGA2 were identified as the direct downstream targets that partially mediated the let-7 effects (11).

Interestingly, a recent study from the same group suggested that miRNAs besides let-7 might also play a role in regulating BCSCs because overexpression of let-7 alone was not sufficient to completely block the tumor formation and progression (17). Subsequently, miR-30 was found to be one of the miRNAs markedly reduced in BCSCs and to negatively modulate the stemness of BCSCs. Overexpression of miR-30 in BCSCs not only diminished their self-renewal ability but also reduced anoikis resistance and increased apoptosis by directly targeting ubiquitin-conjugating enzyme 9 (UBC9) and integrin β3 (ITGB3). Conversely, knocking down endogenous miR-30 with antagonomers enhanced self-renewal, tumor regeneration, and metastasis in differentiated breast cancer cells. Impressively, a more complete inhibition of self-renewal and mammospheres in BCSCs was observed when both let-7 and miR-30 were introduced at the same time, compared with transfecting either miRNA alone (17). The synergistic BCSC-inhibitory effects of let-7 and miR-30 on BCSC self-renewal suggest that multiple miRNAs may distinctively and concertedly regulate CSC properties (Fig. 1A).

miRNA expression profiling in purified CD44^+CD24^-/lo BCSCs identified 37 miRNAs to be differentially expressed in these cells with miR-200 family significantly downregulated in both BCSCs and normal mammary stem and/or progenitor cells (12). Functional studies showed that overexpression of miR-200c reduced the clonogenic and tumor-initiation activities in BCSCs and suppressed formation of mammary ducts by normal mammary stem cells. The stem cell factor BMI-1 was directly modulated by miR-200c. This work (12), thus, provides a molecular link between normal breast stem cells and BCSCs.

Recently, aldehyde dehydrogenase (ALDH) has emerged as a functional marker for both normal and malignant stem and/or progenitor cell populations in various tissues,
miR-205 levels in metastatic breast cancer cell lines and clinical samples (19).

CSCs are morphologically and phenotypically plastic and possess high migratory and invasive capacities. Several groups have observed that miR-205 and miR-200 family members regulate epithelial–mesenchymal transition (EMT), a process thought to be critical in the metastatic cascade. For example, miR-200 miRNAs and miR-205 are significantly downregulated in cancer cells undergoing EMT and in metastatic breast cancer specimens (20, 21). Overexpression of miR-200 miRNAs prevents TGFβ-induced EMT by negatively regulating the expression of EMT activator ZEB1 (also known as TCF8) and ZEB2 (also known as ZFXH1B and SMAD interacting protein 1 or SIP1). Interestingly, ZEB1 and ZEB2 can also transcriptionally repress the expression of miR-200 miRNAs by binding to their promoter regions, leading to strong activation of EMT. These findings (20, 21) establish a double-negative feedback loop between ZEB1/ZEB2 and miR-200 family miRNAs that, together, regulate an important biological process in tumor development and cancer metastasis.

The studies on miRNAs and BCSCs suggest an emerging theme that may also be applicable to understanding how miRNAs regulate other CSCs. BCSCs possess several fundamental biological properties, including self-renewal, quiescence associated with slow cell-cycle kinetics or differentiation associated with cell-cycle exit, prosurvival and antistress mechanisms (e.g., resistance to anoikis), and high capacities to undergo EMT and to invade, all of which likely contribute to their resistance to anticancer therapies and enhanced tumor-initiating and metastatic potential (Fig. 1A). Distinct miRNAs, via their respective downstream targets, distinctively and concertedly regulate these critical CSC properties. Thus, let-7 mainly restricts cell-cycle progression by targeting RAS, HMG2A, and E2F2; miR-30 may preferentially be involved in modulating the survival and stress responses; miR-200 miRNAs negatively regulate the self-renewal by targeting molecules such as BMI-1; and miR-200 and miR-205 (and miR-205) may regulate EMT, migration, and invasiveness in BCSCs (Fig. 1A).

Glioblastoma multiforme and other brain cancer stem cells

Specific miRNA dysregulation in GBM and other brain CSCs has recently been reported in several studies. By comparing miRNA expression in CD133+ versus CD133− GBM cells, one group reported underexpression of tumor-suppressor miR-451 in the CD133+ population (13). miR-451 is well known to repress Myc expression. Another miRNA expression profiling in human GBM specimens revealed a significant reduction of miR-128 compared with adjacent normal brain tissue (22). Subsequently, miR-128 was shown to inhibit glioma stem cell proliferation in vitro and glioma xenograft growth in vivo. Overexpression of miR-128 significantly blocked glioma CSC self-renewal by directly targeting BMI-1 (22). Finally, miR-34a was found to be downregulated in human glioblastomas (23). Transfection of miR-34a into bulk GBM cells or GBM CSCs caused cell-cycle arrest or apoptosis and also inhibited xenograft growth, mediated by downregulation of multiple...
oncogenic targets, including c-MET, Notch-1/2, and CDK6 (23). These studies in GBM (13, 22, 23) support the concept that several major miRNAs may distinctively and concertedly act together to restrict the key GBM CSC properties (Fig. 1B).

miR-199-5p was downregulated in medulloblastoma, and overexpression of miR-199-5p inhibited proliferation and anchorage-independent growth of medulloblastoma cells by targeting HES-1 (24), a transcription factor of the Notch signaling pathway. Significantly, overexpression of miR-199-5p decreased the CD133<sup>+</sup> subpopulation of cells and inhibited tumor development of medulloblastoma cells.

**Prostate cancer stem cells**

Our group was the first to profile miRNA expression in prostate cancer stem and/or progenitor cells (15). Prostate CSCs (PCSC) with high tumor-initiating and metastatic potential are enriched in the side population (25), CD44<sup>+</sup>, and CD44<sup>+</sup> CD<sub>2</sub>Bl<sup>+</sup> (27) subpopulations. Prostate cancer cells with CD133<sup>+</sup>CD44<sup>+</sup>CD<sub>2</sub>Bl<sup>+</sup> phenotype also show enhanced clonogenic potential in vitro (28). Through an unbiased miRNA expression profiling in 5 PCSC and/or progenitor cell populations purified from prostate cancer xenografts, including 3 CD44<sup>+</sup> populations from the LAPC9, LAPC4, and Du145 tumors, CD133<sup>+</sup> cells from LAPC4 tumors, and CD<sub>2</sub>Bl<sup>+</sup> cells from Du145 tumors, we identified miR-34a, together with let-7b, to be commonly underexpressed in all marker-positive cell populations (15). The underexpression of miR-34a was subsequently corroborated in CD44<sup>+</sup> prostate cancer cells purified from ~20 patient prostate tumors. Overexpression of miR-34a in bulk prostate cancer cells or purified CD44<sup>+</sup> cells by transfecting with mature oligonucleotide mimics or infecting with lentiviral vectors encoding pre–miR-34a exerted pronounced inhibitory effects on tumor growth and metastasis in vivo. In contrast, neutralizing endogenous miR-34a using antagonism in bulk or CD44<sup>+</sup> prostate cancer cells promoted tumor regeneration and metastasis. Strikingly, delivery of miR-34a oligos systemically through tail vein inhibited metastasis to the lung and other organs and prolonged the survival of animals bearing orthotopic human prostate cancer, indicating the therapeutic potential of this miRNA. Mechanistically, miR-34a suppressed PCSC properties as it inhibited prostatesphere establishment, migration and invasiveness of CD44<sup>+</sup> prostate cancer cells, and serial prostatesphere passaging and serial tumor transplantation. Of significance, we showed that CD44 itself represented a direct and relevant downstream target of miR-34a. Hence, the CD44 protein levels decreased in cells overexpressing miR-34a, and knocking down of CD44 functionally phenocopied the miR-34a effects in inhibiting tumor development and metastasis. Our findings (15) shed new light on the mechanisms of miRNA regulation of PCSCs.

**Other cancer stem cells**

Interestingly, miR-34, a transcriptional target of p53, not only inhibits the GBM CSCs (23) and PCSCs (15) but also restrains the biological properties of pancreatic and gastric CSCs (29, 30). Restoration of miR-34 expression in these latter CSCs inhibits sphere formation in vitro and tumor regeneration in vivo (29, 30). HCC CSCs identified by EpCAM<sup>+</sup>AFP<sup>+</sup> marker profile overexpressed the miR-181 family and several miR-17-92 cluster members (14). Inhibition of miR-181 led to a reduction in the number of EpCAM<sup>+</sup> HCC cells and in tumorigenesis, whereas overexpression of miR-181 increased the EpCAM<sup>+</sup> cells. The biological effects of miR-181 might be mediated via targeting caudal type homeobox transcription factor 2 (CDX2), GATA6, and nemo-like kinase (NLK), a Wnt/β-catentin pathway inhibitor (14).

**Therapeutic Implications and Perspectives**

Dysregulation of miRNAs has been intimately implicated in tumor development, and miRNAs may regulate tumorigenesis via modulating CSC properties. Thus, let-7 miRNAs control the cell-cycle and differentiation properties of BCSCs, miR-200c modulates the self-renewal of BCSCs by targeting Bmi-1, and miR-34a restricts the migratory and invasive properties of PCSCs by directly repressing CD44. The new findings discussed above better our understanding of CSC regulation and provide novel insight on developing new strategies to target therapy-resistant cancer cells. Given that CSCs seem to be involved in multiple steps of tumorigenesis, including tumor initiation, tumor maintenance, metastasis, and therapy resistance, and that miRNAs exert a broad regulatory role on tumor development, miRNA-based therapeutics that specifically target CSCs may add novel firepower to the anticancer arsenal, as exemplified by our recent demonstrations of the impressive therapeutic efficacies of systemically delivered miR-34a on preestablished human prostate cancers. As distinct miRNAs seem to distinctively and concertedly regulate key and interconnected biological properties of CSCs (Fig. 1), complete eradication of CSCs and residual tumors may entail manipulations or targeting of multiple miRNAs. In addition to developing miRNAs as anti-CSC therapeutics, miRNA expression profiling in CSCs or specific subtypes of cancer and at various clinical stages may have diagnostic and prognostic values.

**Disclosure of Potential Conflict of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors apologize to colleagues whose original work could not be cited due to space constraint.

**Grant Support**

Work in the authors’ laboratory was supported in part by grants from the NIH (R01-ES015888, R21-ES015893, and R21-CA150009), U.S. Department of Defense (W81XWH-08-1-0472), Elsa Pardee Foundation (D.G. Tang), and MD Anderson Cancer Center grants (CCSG-5 P30 CA016672-34 and ES007784). C. Liu was supported in part by a predoctoral fellowship from the U.S. Department of Defense.

Received March 25, 2011; revised May 23, 2011; accepted May 25, 2011; published OnlineFirst September 13, 2011.
References

MicroRNA Regulation of Cancer Stem Cells

Can Liu and Dean G. Tang

Cancer Res 2011;71:5950-5954. Published OnlineFirst September 13, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-1035

Cited articles
This article cites 30 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/18/5950.full.html#ref-list-1

Citing articles
This article has been cited by 16 HighWire-hosted articles. Access the articles at:
/content/71/18/5950.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.